Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicomide is a prescription dietary supplement combination containing nicotinamide (niacinamide), zinc oxide, cupric oxide (copper), and folic acid. It is specifically formulated for the dietary management of inflammatory skin disorders, most notably acne vulgaris and rosacea. The product works through a multi-faceted approach: nicotinamide and zinc provide potent anti-inflammatory effects, with zinc also potentially regulating sebum production. Folic acid is included to support cellular health and DNA synthesis, while copper is added to the formulation to prevent the potential for zinc-induced copper deficiency. Developed and manufactured by Avion Pharmaceuticals, Nicomide is available as an oral tablet and is intended for patients who are deficient in or at risk of deficiency in these specific nutrients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nicomide.